Perspective Therapeutics reports interim Phase 1/2a data showing 33% and 50% response rates in NET trial
Perspective Therapeutics announced interim results from its Phase 1/2a trial of [212Pb]VMT‑α‑NET in patients with SSTR2‑positive neuroendocrine tumors. Objective response rates were 33% in the 5.0 mCi cohort (46 patients) and 50% in the 6.0 mCi cohort (20 patients). Progression‑free survival was 72% at 18 months across all 68 patients and no dose‑limiting toxicities or treatment‑related discontinuations were observed. The company said it will complete Phase 3 site‑start‑up preparations by year‑end 2026 and aims to begin Phase 3 enrolment in 2027.
Why it matters
The company expects the Phase 3 start in 2027 to be a near‑term catalyst for the stock. Successful Phase 3 initiation could move the asset toward a registrational pathway and potentially increase valuation.
Key facts
- 1Objective response rate was 33% (15 of 46 patients) in Cohort 2 receiving 5.0 mCi. stocktitan.net
- 2Objective response rate was 50% (10 of 20 patients) in Cohort 3 receiving 6.0 mCi. stocktitan.net
- 3Disease control rates were 89% in Cohort 2 and 95% in Cohort 3. investing.com
- 4Progression‑free survival was 72% at 18 months across all cohorts (68 patients). stocktitan.net
- 5No dose‑limiting toxicities, no Grade 4/5 treatment‑emergent adverse events, and no discontinuations due to adverse events were reported. tradingview.com
- 6Phase 3 site‑start‑up preparations are targeted for completion around year‑end 2026, with Phase 3 initiation expected in 2027. tradingview.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.